These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 311893)

  • 1. Immune function determination in patients with bladder cancer.
    Brosman SA; Fahey JL
    Natl Cancer Inst Monogr; 1978 Dec; (49):321-3. PubMed ID: 311893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [T-cell bearing IgG-Fc receptor in patients with bladder cancer].
    Sakai S; Kato N; Ishiyama S; Deguchi T; Fujimoto Y; Muranaka K; Matsuda S; Fujihiro S; Setsuda O; Nishiura T
    Hinyokika Kiyo; 1983 Dec; 29(12):1625-9. PubMed ID: 6610295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The study of infiltrating lymphocytes in the tissues of bladder carcinoma].
    Fujimoto Y; Hasegawa Y; Kato N; Sakai S; Kuriyama M; Kawada Y; Nishiura T; Takeuchi T; Isogai K
    Hinyokika Kiyo; 1983 Sep; 29(9):1037-45. PubMed ID: 6610297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
    Flamm J; Grof F
    Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunocompetence and immunotherapy of patients with cancer of the kidney and bladder].
    Mokhort VA; Grigorovich NA; Strotskiĭ AV; Mavrichev AS
    Urol Nefrol (Mosk); 1986; (1):66-74. PubMed ID: 3513423
    [No Abstract]   [Full Text] [Related]  

  • 6. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of the bladder cancer patient based on in vitro measurements of the immune response.
    Lange PH; Hakala TR; Fraley EE
    Cancer Res; 1977 Aug; 37(8 Pt 2):2885-90. PubMed ID: 326395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
    Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
    Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
    Korovin AI; Savvin VT
    Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of superficial bladder tumors in a hospital department].
    Prekopp G; Rosdy E
    Orv Hetil; 1993 Dec; 134(50):2757-60. PubMed ID: 8265124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
    Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
    Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
    Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
    Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum factors present in patients with carcinoma of the bladder: effect on cell-mediated immunity].
    de la Fuente M; Aranda E; Molina I; Sánchez Guijo P; Peña J
    Rev Esp Oncol; 1984; 31(2):257-64. PubMed ID: 6336253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy: concepts and nursing implications.
    McCalla JL
    Nurs Clin North Am; 1976 Mar; 11(1):59-71. PubMed ID: 1083016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
    Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
    Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Zeta chain level of T and NK cells in patients with renal-cell carcinoma and bladder cancer and its clinical significance].
    Han Y; Li CL; Lu L; Zhou CX; Ma WB; Wang DM; Zhang SR
    Zhonghua Zhong Liu Za Zhi; 2004 Mar; 26(3):158-60. PubMed ID: 15196436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.